71 results about "Drug Sample" patented technology

The invention discloses an intelligent detection method for medicine components and medicine quality, and belongs to the field of artificial intelligence. The method comprises the following steps: acquiring a drug sample solution and a control drug solution, and injecting the drug sample solution and the control drug solution into a high performance liquid chromatography system; determining whether operation parameters of the high performance liquid chromatography system need to be adjusted or not; determining operation parameter adjustment information, and continuously updating operation parameters of the high performance liquid chromatography analysis system until a complete drug sample chromatogram and a complete control drug chromatogram are obtained; determining medicine component information and impurity component information of the sample medicine; and determining whether the sample medicine reaches a preset medicine quality evaluation standard or not according to the medicine component information and the impurity component information, and if the preset medicine quality evaluation standard is reached, determining that the sample medicine passes quality detection. According to the scheme, the manual operation time and personal errors can be reduced, the detection efficiency and accuracy are improved, and the analysis result is more accurate and stable.

The invention provides a medicine quality detection method and system based on component analysis, and the method comprises the steps: S100, carrying out the pretreatment of a to-be-detected medicine sample, and obtaining the pretreated to-be-detected medicine sample; s200, detecting the pretreated to-be-detected drug sample by using a gas chromatograph to obtain a first chromatogram of the to-be-detected drug sample; s300, carrying out data processing on the first chromatogram, and identifying the target component in the to-be-detected drug sample according to the first chromatogram after data processing, through a highly automatic operation process and an accurate data processing mechanism, the personal error is significantly reduced, the accuracy and efficiency of drug quality detection are significantly improved, and the detection efficiency is improved. The intelligent degree, the usability and the reliability of the system are improved to a great extent.

The invention relates to the technical field of drug analysis, and provides a fluticasone propionate bulk drug particle size distribution analysis method, which comprises: carrying out dispersion treatment on a screened drug sample to obtain a dispersed drug sample; analyzing a bubble secretion state of the dispersed drug sample, and when the bubble secretion state meets a preset state, obtaining a standing drug sample; collecting a near infrared spectrum when the medicine sample is stirred, analyzing a particle dispersion state of the medicine sample after standing, and obtaining the stirred medicine sample when the particle dispersion state meets a preset state; collecting multiple groups of particle size distribution parameters of the stirred drug sample under multiple groups of preset experiments, collecting working environment parameters, constructing a regression model of the to-be-analyzed drug sample, analyzing optimal parameters by using the regression model, and analyzing the drug particle size distribution state of the to-be-analyzed drug sample by using the optimal parameters. According to the method, the accuracy of the particle size distribution of the fluticasone propionate raw material medicine can be improved.

The invention provides a liquid chromatography method for simultaneously detecting ADC drug antibody coupling ratio and free small molecule content and application thereof, the method comprises the following steps: detecting and analyzing an ADC drug sample by hydrophobic interaction chromatography, the wavelength collection range of a detector in the chromatographic condition comprises 270nm-290nm and 340nm-390nm; the drug antibody coupling ratio is calculated based on data of the wavelength of 270-290 nm, and peaks belong to an uncoupled antibody peak, a D2 peak, a D4 peak, a D6 peak or a D8 peak; the proportion of each peak area reflects proportion distribution of different coupling ratios, and carrying out weighted calculation on the peak areas to obtain an average drug antibody coupling ratio; and calculating the content of the free small molecules based on the data of the wavelength of 340-390nm, assigning the peak to a coupled antibody peak and a free small molecule peak, and calculating the ratio of the peak area of the free small molecules to the total peak area to obtain the content of the free small molecules.

The invention belongs to the technical field of biological control, and relates to a preparation method of prodenia litura nuclear polyhedrosis virus concentrate, which comprises the following steps: cultivating and hatching prodenia litura eggs at constant temperature, culturing the prodenia litura eggs in a dark place into 4-day-old larvae, performing virus infection and proliferation on the 4-day-old larvae, collecting and screening dead insects with strong toxicity and early death as virus semi-finished products, and refrigerating and storing the virus semi-finished products. And finally, preparing the virus semi-finished product into mother powder to obtain the prodenia litura nuclear polyhedrosis virus mother drug. The method comprises the following steps: extracting a parent drug sample to obtain a virus polyhedrosis, extracting a DNA comparison gene sequence of the virus polyhedrosis, prodenia litura nuclear polyhedrosis virus which is identified as prodenia litura nuclear polyhedrosis virus when the similarity between the virus polyhedrosis and Spodoptera litura Nucleoplydrovirus reaches 80% or above, and measuring various performance indexes, so that the prodenia litura nuclear polyhedrosis virus can be identified as prodenia litura nuclear polyhedrosis virus. The prodenia litura nuclear polyhedrosis virus mother drug prepared by the preparation method is used for preventing and treating lepidoptera pests such as prodenia litura, has important significance, has good development and application prospects, and has application value in preparation of insecticides and prevention and treatment of flat thorn moths.

The present invention relates to the technical field of pharmaceutical analysis, and specifically provides a method and system for detecting the components of drugs based on basic pharmacy, including the following steps: Based on the detected drug sample, measure the weight of the drug sample, add a solvent for dissolution according to a preset ratio, combine dilution and mixing, record the color, viscosity, and pH value of the solution, and generate a standardized sample solvent. In the present invention, by standardizing the drug sample, the measurement baseline is ensured, the result deviation is reduced, the credibility of the data is improved, the changes in particle size and quantity are monitored in real time, the understanding of the dissolution process is enhanced, the impedance change of the drug solution is evaluated by monitoring the current response at multiple frequencies, the analysis of electrochemical properties is strengthened, impurities are accurately detected, the chemical properties data of the drug are provided by combining the determination of spectral absorption and fluorescence characteristics, the composition components of the target drug are identified, the drug formula is ensured to meet the specified standards, and the safety and effectiveness of the drug are guaranteed.

The invention discloses a drug open set identification method based on an interval variable-free elimination feature selection algorithm. The method comprises the following steps: S1, preparing a sample; s2, carrying out sample spectrum collection; s3, removing abnormal heroin samples and methamphetamine samples, and reducing noise in the spectrum data of the samples; s4, performing feature selection on the preprocessed spectrum by using an interval variable-free elimination feature selection algorithm, and determining a feature spectrum section; s5, selecting samples to construct a prediction set, and taking the remaining drug samples as a correction set; s6, establishing a type identification model by adopting a partial least square method; and step S7, comparing the type identification accuracy of the two drugs. The drug open set identification method based on the interval variable-free elimination feature selection algorithm is convenient to use, the interval variable-free elimination feature selection algorithm can effectively mine information with high correlation with types in a sample library spectrum, and the accuracy and reliability of model open set identification classification are improved.

The invention relates to a drug sample grinding device for drug detection, which is applied to the field of drug grinding technology. The device comprises a base, a grinding cup, a device cover, a lifting and rotating module, a grinding pestle, a vertical shaft, a code collision block, a spring and a magnetic circle block. The device puts drug particles into the grinding cup, and then the grinding pestle is extended into the grinding cup. The lifting and rotating module drives the grinding pestle to lift and rotate, so that the grinding pestle crushes and grinds the drug in the grinding cup. The grinding pestle repeatedly lifts and lowers during the grinding process, and the magnetic force of the magnetic circle block and the code collision block is used to repel each other. When the grinding pestle moves downward, the code collision block rises in the opposite direction. When the grinding pestle moves upward, the code collision block descends and hits the grinding pestle, so that the drug attached to the grinding pestle is shaken off, and the drug powder is shaken back to the grinding cup for redistribution, so that multiple grinding operations of the drug are convenient, the uniform grinding effect of the drug is effectively improved, and the grinding time of the drug is effectively reduced.

The invention discloses an in-vitro release test method and a content analysis method of a liposome drug, and the method comprises the following steps: mixing a buffer agent and a surfactant in a dissolution cup to obtain a mixed solution, and adding a regulator into the mixed solution to obtain a dissolution medium; adding liposome powder into water for dissolving, and then adding the dissolution medium for dilution to obtain a sample solution; putting the dissolution cup into a dissolution instrument, heating at a preset temperature, and connecting a dialysis tube to the dissolution instrument through an adapter; adding the sample solution into the dialysis tube, mixing the sample solution with the dissolution medium, collecting a drug sample at a specific time point, and analyzing the drug sample to obtain the release rate of the liposome drug. According to the method, the release process of the liposome drug in a living body can be more accurately simulated, and the release rate of the in-vitro release method of the liposome drug is greatly improved.

The invention discloses online detection equipment for a medicine material, relates to the technical field of medicine material detection, and solves the problem of detection distortion caused by slight inclination of a medicine sample. The equipment comprises an equipment shell, a console and a detection bin, wherein a state detection assembly and an infrared detection assembly are arranged in the detection bin. An integrated circuit board in the console is integrated with a sensing acquisition module, a data processing module and a control module, the data processing module comprises a tiny inclination identification unit, a spectrum offset correction unit and a component data correction unit, and the real component content is calculated after the inclination angle is identified through pressure data and spectrum distortion is corrected. And the control module judges the qualified state of the sample in combination with a preset standard, controls the equipment to operate and sends a regulation instruction to an external production system. According to the equipment, the detection accuracy and the operation convenience are improved, the linkage of detection and production is realized, the online quality control requirement is met, and reliable support is provided for medicine production quality control.

The invention discloses a multi-mode medicine component detection method and system, and relates to the technical field of medicine component detection. Comprising the following steps: acquiring an initial attribute: dividing a medicine needing to be detected into at least two medicine samples, selecting one of the medicine samples, putting the selected medicine sample into a first detection instrument, and acquiring an initial environment attribute of the medicine sample in a detection starting stage to obtain a first starting attribute; and attribute grade division: dividing the environment attribute into at least two grades, and performing grade division on the first startup attribute to obtain a first sample attribute item. When multi-mode detection is carried out, the temperature is high during follow-up detection, the temperature is reduced through the temperature control system, the temperature is low, the temperature is increased through the temperature control system, the number of dust particles is large, the dust particles are sucked out through the suction equipment, the number of the dust particles is small, and external dust particles are sprayed into a drug sample through the spraying equipment; and the consistency of detection results of different detection instruments is greatly improved.

The application discloses a drug qualitative detection method based on multi-concentration mixed SERS data, comprising the following steps: constructing a data set of different concentrations of drugs based on SERS spectra of the same drug at high and low concentrations; mixing SERS spectrum data of low and high concentrations in the data set to construct a mixed data set; optimizing hyperparameters of a random forest model based on an improved NSGA-II algorithm to construct an optimized classification model; and classifying drugs based on the mixed data set and the optimized classification model. The application effectively improves the classification accuracy of machine learning models for low-concentration drug samples by mixing SERS data sets, and solves the problem of reliability decline of the prior art on low-concentration samples. In the hyperparameter optimization of the machine learning model, the improved NSGA-II algorithm is used for model hyperparameter optimization, which can simultaneously process multiple conflicting objectives to achieve a balance between model accuracy and efficiency.

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.

The invention relates to the technical field of medicine analysis, in particular to a medicine component detection method and system based on basic pharmacy, and the method comprises the following steps: detecting a medicine sample, measuring the weight of the medicine sample, adding a solvent according to a preset proportion for dissolving, combining dilution and mixing, and recording the color, viscosity and ph value of the solution, and generating a standardized sample solvent. According to the invention, standardization processing is carried out on a drug sample, a measurement base line is ensured, result deviation is reduced, data credibility is improved, particle size and quantity changes are monitored in real time, understanding of a dissolution process is improved, and analysis of electrochemical properties is enhanced by monitoring current response and evaluating impedance changes of a drug solution under various frequencies. Impurities are accurately detected, spectral absorption and fluorescence characteristic determination are combined, chemical characteristic data of drugs are provided, components of target drugs are recognized, it is ensured that the formula of the drugs meets the specified standard, and the safety and effectiveness of the drugs are guaranteed.

The embodiment of the invention provides a medicine component identification method and related equipment, and belongs to the technical field of medicine identification. The method comprises: acquiring preset drug sample data including positive drug sample data and negative drug sample data, the positive drug sample data including a first thin-layer chromatography, and the negative drug sample data including a second thin-layer chromatography; constructing a model training map set through the first thin-layer chromatography map to train a preset twin neural network model to obtain a first twin neural network model; constructing a model test atlas set through the first thin-layer chromatography atlas and the second thin-layer chromatography atlas, and performing parameter optimization on the model in combination with the model training atlas set to obtain a target neural network model; and inputting the to-be-identified thin-layer chromatogram into the target neural network model for component identification analysis to obtain a component identification result. According to the embodiment of the invention, reference substances and reference medicinal materials are not used as much as possible in medicine identification, and the purposes of economy, greenness and environmental protection are achieved.

Aspects and embodiments relate to apparatus and methods to identify whether a drug is present in a provided sample. One aspect provides a drug detection method to identify whether a drug is present in a provided sample, the method comprising: determining a first fluorescence spectral matrix associated with the provided sample by: excitation of the provided sample at a first excitation wavelength; and receiving a fluorescence emission spectrum generated by the provided sample at the first excitation wavelength; repeating the excitation and receiving steps across a range of excitation wavelengths which differ from the first excitation wavelength; determining a wavelength for irradiation of the sample to induce a photochemical change in the provided sample and irradiating the provided sample with radiation having the determined wavelength; determining a second fluorescence spectral matrix associated with the provided sample by: excitation of the provided sample at a first excitation wavelength; and receiving a fluorescence emission spectrum generated by the provided sample at the first excitation wavelength; repeating the excitation and receiving steps across a range of excitation wavelengths which differ from the first excitation wavelength; comparing the determined first and second fluorescence spectral matrix associated with the provided sample with a library of first and second fluorescence spectral matrices obtained from a plurality of drug samples; and if a match within a predetermined threshold is revealed by said comparison, triggering a positive identification of a drug in the provided sample. Aspects recognise that the rapid detection of certain drugs can be enhanced by augmenting a fluorescence spectral fingerprint based detection methodology with photochemical reactivity tracking. The hybrid photochemical fingerprinting methodology in accordance with aspects allows for capture of information on both: new fluorescent species that emerge as a result of a specifically induced photochemical reaction(s) notable detectable drugs, but also the loss of fluorescent / absorptive species as they are photochemically degraded. Both such physical changes are reflective of the specific chemistry of the analyte (drug) which is being tested for.

The utility model discloses a multi-functional sampler for medicine quality detection, which comprises a cylinder body, the outer wall of one side of the cylinder body is fixedly connected with a handle, the top of the cylinder body is in threaded connection with a top cover, the top of the top cover is fixedly connected with a feeding channel, the inner wall of the cylinder body is provided with a material collecting box, and the inner wall of the material collecting box is provided with a crushing treatment mechanism. And a ventilation treatment mechanism is arranged on the inner wall of the material collecting box. Solid medicine entering from the feeding channel can be loaded by arranging the material collecting box, the medicine can be crushed by arranging the crushing treatment mechanism in the material collecting box, the medicine can be blown away by arranging the ventilation treatment mechanism in the material collecting box, the medicine crushing uniformity is guaranteed, and the medicine crushing efficiency is improved. The medicine can be filtered by arranging the filter plate, and further grinding and refining treatment can be performed on the medicine by arranging the grinding and refining mechanism in the material guide channel, so that the refining degree of the medicine sample finally collected in the bottom cover is ensured.

The invention discloses a drug stability analysis system, which relates to the technical field of drug analysis and comprises a sample data acquisition module, a data fusion and regulation module, an intelligent analysis and state judgment module and a result output and trend prediction module, through comprehensive application of the optical imaging technology, the fluorescence imaging technology and the infrared imaging technology, multi-dimensional and all-directional scanning of a drug sample in the stability testing period is achieved, the comprehensiveness and accuracy of data acquisition are remarkably improved, the optical imaging technology captures macroscopic surface morphology information of a drug, and the stability of the drug sample is improved. The fluorescence imaging technology is used for carrying out visual tracking on specific components in the medicine to obtain component distribution information, and the infrared imaging technology is used for analyzing chemical bond vibration conditions among medicine molecules to obtain chemical composition information, so that materials are provided for subsequent data analysis and processing.

The present invention relates to microbiology and plant pathology technology, and specifically to a method of using a small centrifuge tube to mix a small amount of drug sample liquid with water agar under the working condition of a microplate mixing station with a temperature system of 65°C to prepare an agar microplate containing drugs. The main components of the microplate mixing station include a temperature control body A, a centrifuge tube preheating component B for mixing samples, a drug sample preheating component C, a gun head preheating component D, and a glass slide preheating iron box component E. The main steps of the preparation method of the drug microplate are as follows: 1) preparing drug samples, 2) preparing water agar for mixing samples, 3) preparing gun heads, 4) starting the microplate mixing station to enter the working state, 5) preheating samples, 6) preheating glass slides, 7) transferring sample liquid, 8) transferring water agar, 9) mixing sample liquid and water agar, and 10) dripping and developing into a drug microplate. The advantages of the present invention are as follows: 1) small centrifuge tubes are commonly used consumables in biological laboratories and are convenient for use. 2) the total amount of drug samples required is very small; 3) the obtained drug microplate is convenient for subsequent biological assays and microscopic observations.

The present application discloses an intelligent detection method for drug components and drug quality, and the present application belongs to the field of artificial intelligence. The method includes: obtaining a drug sample solution and a control drug solution, and injecting the drug sample solution and the control drug solution into a high performance liquid chromatography analysis system; determining whether it is necessary to adjust the operating parameters of the high performance liquid chromatography analysis system; determining the operating parameter adjustment information, and continuously updating the operating parameters of the high performance liquid chromatography analysis system until a complete drug sample chromatogram and a complete control drug chromatogram are obtained; determining the drug component information and impurity component information of the sample drug; determining whether the sample drug meets the preset drug quality evaluation standard according to the drug component information and the impurity component information. If the preset drug quality evaluation standard is met, the sample drug passes the quality inspection. This solution can reduce the manual operation time and human error, improve the detection efficiency and accuracy, and make the analysis results more accurate and stable.

The invention discloses an in-vitro unknown drug photoionization mass spectrometry rapid qualitative analysis method, which comprises: S1, dissolving a captured suspected drug sample in an acetone or methanol solution, taking out the supernatant, and transferring into a sample bottle; s2, selecting a polar or non-polar SPME probe to penetrate through the sample bottle isolation pad to be inserted into the sample bottle isolation pad, and extracting; and S3, inserting the probe tube into the sample inlet, pushing the handle rod, extending out of the probe extraction head, and performing thermal desorption to desorb the sample to be detected and enter a mass spectrum ionization area. According to the method, richer ionized ion fragment information and molecular ions are provided in the rapid qualitative analysis and accurate identification process of on-site investigation of drugs and precursor chemicals by using a miniaturized mass spectrum technology, and molecular structure information can be provided for analyzing chemical components of unknown novel drugs by using a compound mass spectrum library.

The utility model discloses sampling storage equipment for pharmaceutical analysis, which comprises a low-temperature storage box main body and an upper cover, the top of the low-temperature storage box main body is provided with the upper cover, the center of the top of the upper cover is provided with a control seat, and the top of the control seat is provided with a display screen for displaying the internal temperature of the low-temperature storage box main body. One side of the control seat is provided with a power supply socket used for being connected with an external power supply; and four groups of opposite mounting seats are fixedly mounted at two ends of the center of the bottom of the upper cover. According to the low-temperature preservation box, the low-temperature preservation box body, the upper cover, the control base, the display screen, the power socket, the mounting base, the ultraviolet disinfection lamp, the lens and other parts are arranged and used in cooperation, so that the surfaces of glass test tubes for storing medicine in the low-temperature preservation box body are conveniently disinfected and sterilized, bacterium breeding is reduced, and pollution to medicine samples is reduced; and meanwhile, through cooperation of a lens and an ultraviolet disinfection lamp, the interior of the low-temperature preservation box body can be disinfected and sterilized comprehensively.

The invention relates to the technical field of medicine sample reservation management, in particular to a medicine sample reservation management method based on artificial intelligence and an intelligent management platform. The method comprises the following steps: setting a sample reserving time limit: collecting sample information of a medicine, and setting the sample reserving time limit of a sample according to the sample information; the samples are subjected to storage position distribution through an artificial intelligence algorithm, environment parameters of the storage positions are monitored, and the positions of the samples are monitored; sample receiving management: carrying out identity authentication when the sample is received, and carrying out sampling control and weighing monitoring on the sample; and sample destruction management: carrying out residue detection on the sample, and carrying out evidence storage management through a block chain. According to the method, the whole-process closed-loop management from reserved sample setting to destroying is realized, the manual dependence degree is remarkably reduced, and the management efficiency is improved. In addition, real-time sample tracking and management are achieved, the problems that information transparency is insufficient, and the manual operation process is complex and tedious are effectively solved, and the safety and reliability of medicine management are improved.

The invention belongs to the technical field of bioinformatics, and particularly relates to a structure-based drug design model integrating a Bayesian flow network and a diffusion model. The drug design model integrates the advantages of a Bayesian flow network and a diffusion model through a stochastic differential equation. Atomic coordinates are sampled through a stochastic differential equation, and atomic types are sampled through Bayesian flow, so that the sampling time is shortened, and the attributes of molecules are improved. In addition, a continuous time loss function with an analytic solution is introduced, and the stability of the stochastic differential equation is improved by realizing smoother target distribution conversion. Compared with other models on a common data set CrossDocked 2020 in the field, the drug design model achieves better effects in the aspects of binding affinity of generated molecules, drug sample indexes and conformation stability, and the sampling efficiency is improved by 25%.

The embodiment of the application provides a drug component identification method and related equipment, and belongs to the technical field of drug identification. The method comprises the following steps: obtaining preset drug sample data, including positive drug sample data and negative drug sample data, wherein the positive drug sample data comprises a first thin layer chromatogram, and the negative drug sample data comprises a second thin layer chromatogram; constructing a model training atlas set through the first thin layer chromatogram, so as to train a preset twin neural network model, and obtain a first twin neural network model; constructing a model test atlas set through the first thin layer chromatogram and the second thin layer chromatogram, so as to optimize parameters of the model in combination with the model training atlas set, and obtain a target neural network model; and inputting a to-be-identified thin layer chromatogram into the target neural network model for component identification analysis, and obtaining a component identification result. The embodiment of the application can try not to use control samples and control medicinal materials in drug identification, so that the economic, green and environmentally-friendly purposes are achieved.

The disclosure provides in some aspects test kits useful for testing a sample of a substance for the presence of one or more chemical compounds, for example for drug checking, such as testing a drug sample for an adulterant or a contaminant. The disclosure provides in some further aspects single use test kits for drug checking, including test kits structured as an integrated single unit, and which may comprise multiple separable pouches, including where one pouch serves as a fluid reservoir for dissolving a test sample in a solvent for testing, such as dissolving a drug sample in water. The disclosure provides in yet further aspects methods of using the disclosed test kits, such as for drug checking. The disclosed integrated single use drug test kits are portable, user-friendly, cost-effective, efficient, reliable, and accurate, and have such other advantages and improvements over prior art test kits as are illustrated herein.

The invention discloses a small nucleic acid medicine purification process, and belongs to the technical field of nucleic acid purification. A small nucleic acid drug purification process comprises the following steps: S1, mixed mode chromatography: dissolving a small nucleic acid drug crude product in a buffer solution containing 20mM phosphate and 10% acetonitrile to obtain a solution A; loading the solution A to a mixed-mode chromatographic column with a mixed-mode chromatographic column medium comprising functionalized agarose gel, and carrying out gradient elution to remove impurities; eluting the target product with a buffer solution containing 2M NaCl and 10% acetonitrile; s2, size exclusion chromatography: diluting a small nucleic acid drug sample eluted by mixed mode chromatography with an equilibrium buffer solution, loading the sample into a size exclusion chromatography column, performing isocratic elution with the equilibrium buffer solution, monitoring an ultraviolet absorption signal at 260nm, collecting an elution peak, and freeze-drying to obtain a high-purity small nucleic acid drug; the functionalized agarose gel is agarose gel for simultaneously modifying a quaternary ammonium salt group and an alkyl group.

The utility model relates to the technical field of sampling devices, in particular to a powder sampling device for medicine production, which comprises a handle and a sampling assembly, and the sampling assembly comprises a sleeve, a moving block, a connecting rod and a plurality of shielding parts; the sleeve is provided with a plurality of sampling ports; when medicine powder is sampled, a worker holds the sleeve by hand, inserts the sleeve into a medicine sample, then pulls the handle to move upwards, the handle drives the connecting rod and the multiple shielding components to move upwards, the multiple shielding components and the multiple sampling openings are staggered to be exposed out of the sampling openings, then the sleeve is rotated, and the medicine powder is sampled. During sampling, medicine powder can enter the multiple sampling openings with different height positions, then the handle is pushed to move downwards, the multiple shielding components return to the side edges of the sampling openings again, the sampling openings are closed, and sampling is completed by moving the sleeve out of a medicine sample. By means of the mode, medicine powder at different depth positions of a medicine sample can be sampled at the same time, and the medicine powder sampling efficiency is improved.

The utility model relates to the technical field of dispensing barrel sampling devices, and particularly discloses an automatic dispensing barrel sampling device which comprises a circulating assembly, a sampling assembly is arranged on one side of the circulating assembly, a moving assembly is arranged on the other side of the circulating assembly, and a supporting table is arranged below the sampling assembly. The sampling assembly comprises a dispensing barrel located on the supporting table, a stirring motor is arranged on the dispensing barrel, a stirring shaft connected with the stirring motor is arranged in the dispensing barrel, and stirring blades are arranged on the stirring shaft; the automatic sampling device for the dispensing barrel is simple in overall structure and reasonable in design, and a worker can sample a medicine sample conveniently; due to the design of the circulating assembly, the automatic operation of the sampling process of the medicine in the medicine dispensing barrel can be realized, so that a relatively uniform sampling sample can be obtained; due to the design of the moving assembly, manpower time and manpower cost can be saved, and manual operation errors are reduced, so that the automation degree of operation is improved, and the working efficiency of sampling in the dispensing barrel is improved.

The utility model discloses a novel drug stability test box which comprises a tripod and a thermal stability box fixedly installed at the top end of the tripod, a sealing cover is hinged to the position of an opening in the top end of the thermal stability box, and a barrel type middle heat supply unit is arranged in the central axis area in the thermal stability box below the sealing cover. A plurality of column bases used for bearing medicine samples are installed at the bottom of the thermal stabilization box in an annular array mode, an annular base is fixed to the center of the bottom of the thermal stabilization box, and a multidirectional synchronous air blowing structure used for blowing air towards the periphery is installed in the annular base. According to the utility model, heat can uniformly cover each corner in the test box and the surface of a drug sample, so that the temperature of each position is approximately consistent, and the thermal stress difference possibly generated when the drug sample is heated can be obviously reduced due to uniform heating distribution; the stability performance of the medicine under different temperature storage conditions can be accurately evaluated.